ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1275

Pneumococcal Vaccination Compliance Rate Among Lupus and Rheumatoid Arthritis Patients in Rheumatology Fellow’s Cllinic

Sana Kang1, George Gennaoui2 and J. Patricia Dhar3, 1Ascension St John Hospital, Chesterfield, MO, 2Ascension St. John Hospital, St. Clair Shores, MI, 3Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI

Meeting: ACR Convergence 2022

Keywords: health status, prevention, quality of care, rheumatoid arthritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Measures and Measurement of Healthcare Quality Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: The US Center for Disease Control and Prevention recommends that adults ages 19 years and older, with immunocompromising conditions should receive a dose of pneumococcal conjugate vaccine (PCV13) first, followed by a dose of pneumococcal polysaccharide vaccine (PPSV23) at least 8 weeks later. Additionally, those who received PPSV23 before age 65 years for any indication should receive another dose of vaccine at age 65 years or later if at least 5 years have elapsed since their previous PPSV23.1 The objective of this project was to determine if patients with a diagnoses of systemic lupus erythematosus (SLE) and/or rheumatoid arthritis (RA) seen in our academic rheumatology practice were receiving the recommended pneumococcal vaccination schedule for immunosuppressed conditions.

Methods: A retrospective chart review was performed for patients ages 18 years and older with a diagnosis of RA and/or SLE in our academic rheumatology clinic who were on immunosuppressive medications including methotrexate, corticosteroids, azathioprine, adalimumab, etanercept, certolizumab, anakinra, baricitinib, tocilizumab, upadacitinib, apremilast, tofacitinib, rituximab, mycophenolate mofetil, or cyclophosphamide from 7/1/2019 to 1/31/2021. Data were analyzed using the chi-squared test; a p-value less than 0.05 was considered to indicate statistical significance.

Results: We reviewed the charts of 329 patients who had mean age of 56.6 ± 14.8 years, with 84.8% (279) female and 43.8% black (144). Overall, 100/329 (30.4%) patients with a diagnosis of systemic lupus erythematosus and/or rheumatoid arthritis were vaccinated with first dose of Prevnar and 38/329 (11.6%) received PPSV23 only. Higher vaccination prevalence was observed among patients ages 65 years and older. The patients who received PPSV23 or PCV 13 before initiation of immunosuppressive medications was noted to have mean age of 66 years.Only 58/329 (17.6%) of patients received PPSV23 or PCV13 before initiation of immunosuppressive medications.

Table 1 shows compliance with vaccine recommendation by age and type of medications taken.

Conclusion: This study demonstrates that about 70% of patients with a diagnosis of systemic lupus erythematosus and/or rheumatoid arthritis in an academic rheumatology clinic at Ascension St. John Hospital did not receive pneumococcal vaccination as recommended by the CDC. Educational intervention to increase awareness of the pneumococcal vaccine schedule is needed to improve pneumococcal vaccine uptake in patients with rheumatoid arthritis and SLE, particularly those less than 65 years of age.

Supporting image 1

Table 1 shows compliance with vaccine recommendation by age and type of medications taken.


Disclosures: S. Kang, None; G. Gennaoui, None; J. Dhar, None.

To cite this abstract in AMA style:

Kang S, Gennaoui G, Dhar J. Pneumococcal Vaccination Compliance Rate Among Lupus and Rheumatoid Arthritis Patients in Rheumatology Fellow’s Cllinic [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/pneumococcal-vaccination-compliance-rate-among-lupus-and-rheumatoid-arthritis-patients-in-rheumatology-fellows-cllinic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pneumococcal-vaccination-compliance-rate-among-lupus-and-rheumatoid-arthritis-patients-in-rheumatology-fellows-cllinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology